Document is current

Article History

Received: 7 July 2025

Accepted: 16 July 2025

First Online: 31 July 2025

Declarations

:

: Jalid Sehouli reports receiving research support from Roche Pharma, AstraZeneca, Bayer, Clovis Oncology, GlaxoSmithKline, Lilly, Iqvia, Mural, and MSD. He has received honoraria from GlaxoSmithKline, PharmaMar, AstraZeneca, Clovis Oncology, Bayer, Roche Pharma, Vifor Pharma, Hexal AG, Novartis Pharma, Eisai, Esteve Pharmaceuticals, Incyte Biosciences, Phytolife Nutrition, JenaPharm, Kyowa Kirin, Oncoinvent AS, Daiichi, Medtronic Covidien, AMGEN, AbbVie, Corcept Therapeutics, Gilead Sciences, and Myriad. He has served in consulting or advisory roles for Merck/Pfizer, PharmaMar, Clovis Oncology, AstraZeneca, Roche Pharma, GlaxoSmithKline, MSD, Eisai, Novocure, Oncoinvent, Intuitive Surgical, Seagen, Bayer Vital, Mundipharma, Sanofi-Aventis Deutschland GmbH, Immunogen, Tubulis GmbH, Daiichi Sankyo, Bristol Myers Squibb, Karyopharm Therapeutics, and Corcept Therapeutics. Klaus Pietzner reports receiving honoraria or travel support from AstraZeneca, Roche, Tesaro/GlaxoSmithKline, MSD Sharp & Dohme, Novartis, Eisai, Immunogen/AbbVie, and Daiichi Sankyo. He has served in consulting or advisory roles for AstraZeneca, Roche, Tesaro/GlaxoSmithKline, MSD Sharp & Dohme, Novartis, Eisai, Immunogen/AbbVie, Daiichi Sankyo, and Myriad. Anne-Karen Beckerath reports receiving travel support in the form of congress registration fees covered by Gideon Richter. Chiara Flethe, Catherine Krause, Sara Alavi-Demirci and Maximilian Beck declare no competing interests to the content of this manuscript.

: Ethical approval was obtained from the ethics committee of Charité—Universitätsmedizin Berlin (EA1/134/21).

: Participation in the survey was voluntary and anonymous; therefore, no written informed consent was required.